Table of Contents

CHAPTER 4. FOUNDATIONS OF PATENT VALIDITY AND INVALIDITY

I. GENERALLY

II. PRIOR ART

III. PRACTICING THE PRIOR ART

CHAPTER 5. SECTION 101'S SUBJECT MATTER & UTILITY

CHAPTER 6. NOVELTY AND LOSS OF RIGHTS UNDER SECTION 102

CHAPTER 7. OBVIOUSNESS UNDER SECTION 103

I. BACKGROUND TO OBVIOUSNESS

II. OBVIOUSNESS & INVALIDITY

CHAPTER 8. SECTION 112'S BEST MODE

A. STATUTORY PROVISIONS: SPECIFICATION

CHAPTER 9. SECTION 112'S ENABLEMENT

CHAPTER 10. SECTION 112'S WRITTEN DESCRIPTION

CHAPTER 11. SECTION 112'S INDEFINITENESS

CHAPTER 12. SECTION 112'S DEPENDENT AND MEANS PLUS FUNCTION CLAIMS

CHAPTER 13. GENUS AND SPECIES

CHAPTER 14. CLAIMING PRIORITY PROVISIONALS CONTINUATIONS AND DIVISIONALS

CHAPTER 15. CLAIM CONSTRUCTION IN PATENT INFRINGEMENT

CHAPTER 16. LITERAL INFRINGEMENT

CHAPTER 17. DOCTRINE OF EQUIVALENTS INFRINGEMENT

CHAPTER 18. INDIRECT INFRINGEMENT THROUGH INDUCEMENT AND CONTRIBUTORY INFRINGEMENT

CHAPTER 19. INEQUITABLE CONDUCT AND PATENT UNENFORCEABILITY

CHAPTER 20. EQUITABLE DEFENSES TO PATENT INFRINGEMENT

CHAPTER 21. PATENT INFRINGEMENT SAFE-HARBOR EXEMPTIONS

CHAPTER 22. BASICS OF BRAND DRUG APPROVAL PROCESS AND ORANGE BOOK LISTINGS

CHAPTER 23. BRAND SIDE EXCLUSIVITIES

CHAPTER 24. "PAPER NDA" AND SECTION 505(B)(2) APPLICATIONS

CHAPTER 25. ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVAL PROCESS

CHAPTER 26. MECHANICS OF ORANGE BOOK PATENT CERTIFICATIONS AND NOTICE LETTERS

CHAPTER 27. THE 30-MONTH INJUNCTION/STAY

I. GENERALLY

CHAPTER 28. THE PARAGRAPH IV BASED 180-DAY EXCLUSIVITY

CHAPTER 29. FORFEITURE OF THE 180-DAY EXCLUSIVITY

CHAPTER 30. 180 DAY MARKET EXCLUSIVITY UNDER COMPETITIVE GENERIC THERAPY (CGT) INITIATIVE

CHAPTER 31. PREISSUE SUBMISSIONS AND POST-ISSUANCE IPR WITH IMPACTS ON COURT LITIGATION

CHAPTER 32. PATENT INFRINGEMENT DAMAGES AND REMEDIES

CHAPTER 33. DECLARATORY JUDGMENT

CHAPTER 34. CITIZEN PETITIONS

CHAPTER 35. ISSUES RELATING TO THE SIZE/SHAPE/COLOR OF GENERIC PRODUCTS

CHAPTER 36. PHARMACEUTICAL COMPOUNDING AND INTELLECTUAL PROPERTY ISSUES

CHAPTER 37. OVER THE COUNTER (OTC) DRUGS

APPENDICES